References
- Goldstein TC , PaullEO, EllisMJ, StuartJM. Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin. Cancer Res.19(12), 3114–3120 (2013).
- Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415–421 (2013).
- Helleday T , EshtadS, Nik-ZainalS. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet.15(9), 585–598 (2014).
- Nik-Zainal S , Van LooP, WedgeDCet al. The life history of 21 breast cancers. Cell149(5), 994–1007 (2012).
- Burns MB , LackeyL, CarpenterMAet al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature494(7437), 366–370 (2013).
- Burns MB , TemizNA, HarrisRS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet.45(9), 977–983 (2013).
- Ellis MJ , GilletteM, CarrSAet al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov.3(10), 1108–1112 (2013).
- Altelaar AF , MunozJ, HeckAJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet.14(1), 35–48 (2013).
- Lokody I . Cancer genetics: the origin and evolution of an ancient cancer. Nat. Rev. Cancer14(3), 152 (2014).
- Dawson SJ , TsuiDW, MurtazaMet al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med.368(13), 1199–1209 (2013).
- Kidess E , JeffreySS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?Genome Med.5, 70 (2013).
- Asghar U , WitkiewiczAK, TurnerNC, KnudsenES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov.14(2), 130–146 (2015).